Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN) — a first-of-its-kind ...
Myeloma faculty from UT Southwestern Medical Center and pharmacy leaders from Texas Oncology discussed how teclistamab- and ...
*Oya Gilbert is bringing his “Mic Check Myeloma” tour to Chicago. The free event lands at mHub on Saturday, Oct. 24, with ...
Pfizer's revenue swung sharply lower before stabilizing, while Bristol Myers Squibb kept climbing steadily—a divergence that ...
New research links genomic, transcriptomic, and epigenetic features to treatment response in multiple myeloma.
A new study identifies UBA1 as a primary candidate biomarker for multiple myeloma by integrating ubiquitination and ...
Sanofi's CirCLIQ Injector with Enable's enFuse technology administers a subcutaneous formulation of Sarclisa for multiple myeloma.
The five-year, $2.9 million grant from the NCI is planned to fund two phases of clinical trials. A Phase 1b trial plans to enroll up to 18 patients to evaluate the safety of the treatment combination ...
Experts highlight updated findings from CARTITUDE-2, how to mitigate late toxicities, and other key considerations in the modern multiple myeloma landscape.
Matthew J. Frigault, MD, and Adam D. Cohen, MD, outline how updated NCCN guidelines position CAR T-cell therapy in early ...
A phase 2 trial found that ultra-low-dose radiation therapy delivered in one or two sessions relieved painful bone lesions in ...
During a live event, Robert Orlowski, MD, PhD, and participants discussed how access barriers, disease tempo, and bridging choices shape CAR T referral for a patient with early relapsed multiple ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results